CJC-1295 dosage: study administrations
A research value is only useful with its compound, population and question attached.
Human study administrations
The CJC-1295 figures below describe what studies gave their participants. I use them to identify which experiment produced which finding. They provide no personal dose recommendation.
| Human experiment | Reported single subcutaneous administrations | Main question |
|---|---|---|
| Teichman and colleagues | 30 or 60 micrograms per kilogram | GH and IGF-1 response and pharmacokinetics |
| Ionescu and Frohman | 60 or 90 micrograms per kilogram | GH secretion pattern during sustained stimulation |
The Teichman human study and Ionescu and Frohman pulsatility study concern the long-acting compound. A weight-based research value is tied to that study's participants and conditions. CJC-1295 has no validated human dose for the benefits discussed on this site.
Animal study context
The GHRH-knockout mouse experiment used 2 micrograms per dose at 24, 48 or 72 hour intervals. The once-daily condition normalised body weight and length, while the less frequent conditions were progressively less effective. These were mice unable to make GHRH.
That experimental setting is essential. I admire the strength of the result within it and see no route from a mouse growth-rescue experiment to instructions for a healthy person. The species, missing hormone and measured outcome all matter.
No DAC and combination protocols
Online protocols for no-DAC Modified GRF 1-29 or for CJC-1295 with ipamorelin circulate separately from controlled outcome trials. They are anecdotal practices rather than clinical evidence, and no doses or schedules from those accounts are reproduced here.
Modified GRF lacks the DAC compound’s albumin-binding handle and has a shorter duration. The DAC vs no DAC page addresses the names. The combination has a receptor rationale, covered under CJC-1295 and ipamorelin research, but that rationale has not established a human regimen or a performance benefit.
Administration and handling questions
Subcutaneous administration was used in the human CJC-1295 research. That tells us the route behind the published findings. It offers no injection-site, preparation or self-administration guidance.
I cannot supply an answer to “how much should I take” from this evidence. The studies investigated hormone activity; they left clinical efficacy and long-term safety in healthy adults unresolved. CJC-1295 is unapproved for human use. A protocol assembled from isolated research figures would claim more than these experiments established.